03613.HK
Beijing Tong Ren Tang Chinese Medicine Company Limited
HKSE · Healthcare · Medical - Pharmaceuticals · HK
HKD 5.97
+0.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.5B | 1.6B | 1.5B | 1.7B |
| Cost of Revenue | 655.6M | 587.8M | 546.3M | 477.7M | 581.0M |
| Gross Profit | 1.1B | 925.6M | 1.1B | 1.0B | 1.2B |
| Operating Expenses | |||||
| R&D Expense | 11.6M | 11.6M | 9.1M | 12.2M | 7.7M |
| SG&A Expense | 518.5M | 390.4M | 492.0M | 410.3M | 341.7M |
| General & Admin Expense | 139.0M | 183.3M | 191.8M | 179.0M | 154.5M |
| Selling & Marketing Expense | 155.8M | 207.1M | 300.2M | 231.3M | 187.2M |
| Other Expenses | (9.8M) | 51.3M | (12.7M) | 596.0K | (10.8M) |
| Total Operating Expenses | 520.3M | 453.3M | 488.4M | 423.1M | 338.6M |
| Cost and Expenses | 1.2B | 1.0B | 1.0B | 900.8M | 919.5M |
| Operating Income (EBIT) | 558.4M | 472.2M | 576.9M | 624.1M | 811.6M |
| Non-Operating | |||||
| Interest Income | 59.1M | 46.8M | 57.3M | 72.9M | 20.6M |
| Interest Expense | 5.3M | 5.7M | 6.5M | 6.0M | 4.7M |
| Net Interest Income | 59.1M | 41.4M | 50.8M | 66.9M | 15.9M |
| Other Non-Op Income/Expense | 34.9M | 32.5M | 52.8M | 63.6M | 14.4M |
| Non-Operating Income (excl Interest) | (3.8M) | (3.8M) | (59.3M) | (69.6M) | (19.0M) |
| EBT (Pre-Tax Income) | 593.3M | 504.7M | 629.8M | 687.8M | 826.0M |
| Income Tax Expense | 98.2M | 87.8M | 100.6M | 97.2M | 134.7M |
| Bottom Line | |||||
| Net Income | 478.0M | 397.2M | 500.3M | 540.4M | 645.9M |
| Earnings from Cont. Ops | 495.1M | 416.9M | 529.2M | 590.6M | 692.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 478.0M | 397.2M | 500.3M | 540.4M | 645.9M |
| Per Share | |||||
| Basic EPS | HK$0.57 | HK$0.47 | HK$0.60 | HK$0.65 | HK$0.77 |
| Diluted EPS | HK$0.57 | HK$0.47 | HK$0.60 | HK$0.65 | HK$0.77 |
| Revenue Per Share | HK$2.07 | HK$1.81 | HK$1.93 | HK$1.82 | HK$2.07 |
| Shares | |||||
| Basic Shares Outstanding | 837.1M | 837.1M | 837.1M | 837.1M | 837.1M |
| Diluted Shares Outstanding | 837.1M | 837.1M | 837.1M | 837.1M | 837.1M |
| Profitability Metrics | |||||
| EBITDA | 624.7M | 495.5M | 722.3M | 779.5M | 907.6M |
| D&A | 62.5M | 19.5M | 88.1M | 82.5M | 75.5M |
| EBIT | 562.2M | 476.0M | 636.3M | 693.8M | 830.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026